Close Menu

Horizon Discovery

The firm saw steady growth in its research reagents and screening businesses, and a 155 percent revenue increase in its bioproduction unit.

Horizon will help develop the cell line-derived reference material, St. George's will provide clinical samples, and the EMQN will run a validation study.

The partners are planning to integrate the technology into Horizon's research tools and services and to develop it for applications in cell therapeutics.

The firm said it saw a robust contribution in the first half of the year from its Dharmacon business and noted that it increased its reach into the US market.

After acquiring Dharmacon, as well as licensing a wide array of editing technologies, Horizon has built itself into a repository of knowledge and tools.

The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.

In a note to investors, Cowen analyst Doug Schenkel called the decision "odd," and wondered if there would be more to come.

The company said its product revenues for the year rose 101 percent while its services revenues rose 7 percent.

The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price on May 1.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.